Figure 5

Repeated administration of BHV1gG protein does not alter the progression of lupus in NZB/W F1 mice with or without previous treatment with Ad-IFNα. (A) NZB/W F1 mice were injected IV with Ad-IFNα at 12 wks of age and were treated with 500 µg of BHV1gG-Ig three times a week from wk 13 to 21 (early BHV1gG-Ig) or from wk 15 until the end of the experiment (late BHV1gG-Ig). (B) Twenty-four-week-old NZB/W F1 mice were treated with 500 µg of BHV1gG-Ig three times a week until 34 wks of age. Survival (left) and age at proteinuria onset (right) of the mice are shown.